incrementalTreatment update

Avapritinib molecular responses in advanced SM: 30% achieve D816V undetectable

Systemic Mastocytosis →

Summary

Pooled data from EXPLORER and PATHFINDER trials show avapritinib achieves deep molecular responses in advanced SM, with KIT D816V becoming undetectable in bone marrow of 30% of patients — a new response benchmark previously unattainable with midostaurin.

Related genes

KITD816V (c.2468A>T)
The central driver mutation of systemic mastocytosis. Causes constitutive ligand-independent activation of the KIT receptor tyrosine kinase, driving mast cell proliferation, survival, and activation. Arises in early hematopoietic stem/progenitor cells.

Source

Grade Acohort

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis

DeAngelo DJ, Radia DH, George TI, et al. · Blood · 2022

  • •Avapritinib induced 30% molecular response (KIT D816V undetectable) in AdvSM
  • •Deep responses across ASM, SM-AHN, and MCL subtypes
DetailsDOI ↗

More from Systemic Mastocytosis

significantTreatment update

PIONEER 3-year follow-up confirms sustained avapritinib benefit in ISM

significantNew research

Swedish and Danish population-based studies reveal higher SM prevalence than expected

breakthroughTreatment update

Avapritinib FDA-approved for indolent systemic mastocytosis (PIONEER trial)

significantGenetic finding

WHO 2022 and ICC 2022 classification updates published

ID: systemic-mastocytosis-update-4Type: treatment_updateImpact: incremental